Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on trial using depot testosterone undecanoate.

Trial Profile

Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on trial using depot testosterone undecanoate.

Suspended
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Jul 2015 Planned End Date changed from 15 Oct 2014 to 15 Jan 2015 as reported by United Kingdom Clinical Research Network record.
    • 02 Jul 2015 Status changed from recruiting to suspended as reported by United Kingdom Clinical Research Network record.
    • 08 Jan 2015 Accrual to date is 61% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top